These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. Hardinger KL; Murillo D Clin Transpl; 2011; ():401-8. PubMed ID: 22755438 [TBL] [Abstract][Full Text] [Related]
8. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487 [TBL] [Abstract][Full Text] [Related]
9. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614 [TBL] [Abstract][Full Text] [Related]
10. World kidney day 2010: medical aspects of 10 live-donor renal transplantations in a single center from a developing country. Shah PR; Modi PR; Kute VB; Vanikar AV; Patel HV; Gumber MR; Shah VR; Trivedi HL Transplant Proc; 2012 Jan; 44(1):47-8. PubMed ID: 22310575 [TBL] [Abstract][Full Text] [Related]
11. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection. Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384 [TBL] [Abstract][Full Text] [Related]
12. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Stuckey LJ; Kamoun M; Chan KM Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499 [TBL] [Abstract][Full Text] [Related]
13. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation. Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991 [TBL] [Abstract][Full Text] [Related]
15. Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol. Everly MJ; Jahr F; Kaneku H; Trivedi HL; Terasaki PI Clin Transpl; 2009; ():281-93. PubMed ID: 20524292 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Cooper JE; Gralla J; Chan L; Wiseman AC Clin Transpl; 2011; ():359-64. PubMed ID: 22755431 [TBL] [Abstract][Full Text] [Related]
17. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience. Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M Clin Transpl; 2011; ():373-9. PubMed ID: 22755434 [TBL] [Abstract][Full Text] [Related]
19. Analysis of transplant outcomes after five or six human leukocyte antigen-mismatched living donor kidney transplantation. Lee HS; Kim MS; Kim YS; Joo DJ; Ju MK; Kim SJ; Kim SI; Huh KH; Park K Transplant Proc; 2012 Jan; 44(1):273-5. PubMed ID: 22310631 [TBL] [Abstract][Full Text] [Related]